Basal cell carcinomata: Risk factors for incomplete excision and results of re-excision

Masud, Dhalia; Moustaki, Margarita; Staruch, Robert; Dheansa, Baljit

doi:10.1016/j.bjps.2015.12.024

Cited by 41 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, BCCs were excised with a 3 to 5-mm clear margin, depending on the location of the tumor, while SCCs were excised with a 1-cm clear margin and MMs were excised with a 2-cm clear margin. Previous studies have shown a great variability in the re-excision rates ranging from 9% to 75% for BCCs [30]. In our study, the rate of residual tumors resulting in re-excision was 18% for BCCs, 9% for SCCs, and 0% for MMs.…”

Section: Discussionsupporting

confidence: 43%

Evaluation of residual tumors and recurrence rates of malignant melanoma and non-melanoma skin cancer of head and neck region

Kocaaslan¹,

Alakus²,

Saçak³

et al. 2019

Marmara Medical Journal

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate residual tumors and recurrence rates of malignant melanoma (MM) and a nonmelanoma skin cancer of (NMSC) head and neck region. Patients and Methods: Medical data of a total of 398 lesions of 323 patients who underwent surgical excision for a basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM) were retrospectively analyzed. All patients were classified according to age, sex, location of the tumor, histopathological diagnosis, lesion diameter, excision diameter, surgical margin status, and residual lesions and recurrence rates. Results: There were 244 lesions (61.3%) in 189 males and 154 lesions (38.7%) in 134 females. The most common type of skin cancer was BCC in 268 lesions (67%), followed by SCC in 122 (31%), and MM in eight (2%), respectively. Recurrence was seen in 3% of the NMSC cases and in 25% of the MM cases. There was a statistically significant correlation between the histopathological diagnosis and recurrence rates. Compared to NMSC, MM cases had a higher risk for recurrence (p=0.029). Conclusion: Our study results suggest that recurrence is associated with the localization and type of the tumor, but not with the age or sex of the patient.

show abstract

Section: Discussionsupporting

confidence: 43%

Evaluation of residual tumors and recurrence rates of malignant melanoma and non-melanoma skin cancer of head and neck region

Kocaaslan¹,

Alakus²,

Saçak³

et al. 2019

Marmara Medical Journal

View full text Add to dashboard Cite

show abstract

“…Conventional surgery has been reported to result in incomplete excisions in 4.7 % to 24 % of all surgically removed tumors; however, recurrence must be expected in only 26 % to 41 % of BCC lesions following incomplete excision. Moreover, approximately one‐half of the specimens contain no residual tumor tissue following re‐excision . There are, however, no reliable predictive indicators and recurrent tumors may exhibit a more aggressive growth pattern after incomplete excision .…”

Section: Risk Stratificationmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.

show abstract

“…Im Rahmen der konventionellen Chirurgie werden unvollständige Exzisionen in 4,7 % bis 24 % aller operierten Tumoren berichtet, wobei nur in 26 % bis 41 % der unvollständig exzidierten BZK mit einem Rezidiv zu rechnen ist und nach Re‐Exzision etwa die Hälfte der Exzidate keine Tumorresiduen mehr aufweisen . Dennoch gibt es hierfür keine verlässlichen prädiktiven Indikatoren, und Rezidivtumoren können nach inkompletter Entfernung einen aggressiveren Wuchs aufweisen .…”

Section: Chirurgische Therapieunclassified

“…Neuere Daten von Arits et al. zeigen in einer Vergleichsstudie zwischen MAL‐PDT, Imiquimod und 5‐FU, dass 5‐FU in der Behandlung von sBZK etwa gleich effektiv wie MAL‐PDT, jedoch Imiquimod unterlegen ist (Tumorfreiheit nach 12 Monaten: 72,8 % [95 %‐KI 66,8–79,4] für MAL‐PDT, 83,4 % für Imiquimod, 80,1 % …”

Section: Topische Therapieunclassified

S2k‐Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge

Lang

Balermpas²,

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Das Basalzellkarzinom (BZK) ist der häufigste maligne Tumor der hellhäutigen Bevölkerung mit jährlich steigender Inzidenz. Eine Aktualisierung der S2k‐Leitlinie unter Beteiligung aller mit dem Krankheitsbild vertrauten Fachgesellschaften sowie vorangegangener Literaturrecherche ist für die Qualität der Versorgung der betroffenen Patienten von essentieller Bedeutung. Im vorliegenden Teil 2 wird zunächst eine Risikostratifizierung aufgezeigt, bevor die verschiedenen Therapieoptionen diskutiert werden. Zudem werden Prävention und Nachsorge der Erkrankung behandelt.

show abstract

Basal cell carcinomata: Risk factors for incomplete excision and results of re-excision

Cited by 41 publications

References 22 publications

Evaluation of residual tumors and recurrence rates of malignant melanoma and non-melanoma skin cancer of head and neck region

Evaluation of residual tumors and recurrence rates of malignant melanoma and non-melanoma skin cancer of head and neck region

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

S2k‐Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge

Contact Info

Product

Resources

About